Therapeutic strategies for Dravet syndrome: upregulation of endogenous SCN1A and modulation of pathological remodeling
In this project FRRB funds Partner number 1:
- Ospedale San Raffaele – Divisione della Neuroscienza, Principal Investigator Dr. Vania Broccoli
| Pathology of interest: | Dravet syndrome |
| Area of research: | Neurology |
| Start date: | 1st June 2021 |
| End date: | 31st May 2024 |
| Funding: | € 318.800,00 |
| Project partners: |
- Centre national de la recherche scientifique (CNRS) – Leading partner, France - University of Leuven, Belgium - Radboud University, NetherlandsUniversity of Tübingen, Germany |
PROJECT SUMMARY
Dravet syndrome (DS) is a rare, devastating encephalopathy of early childhood characterized by drug-resistant epileptic seizures, cognitive deficits and ataxia. DS is caused by loss-of-function mutations in SCN1A, encoding the main Na+ channel of GABAergic neurons (NaV1.1), which lead to widespread disinhibition of neuronal networks in mouse models that recapitulate DS phenotype and in patient-derived in vitro models.
Although several anti-epileptic drugs are available they are only partially effective against seizures and not against other symptoms.
The overall objective of SCN1A-UP! is to develop more effective treatments for DS by targeting directly the initial genetic dysfunction, SCN1A loss-of-function, as well as other signaling pathways leading to further pathological modifications in neuronal networks (pathological remodeling).
An effective disease-preventing or -modifying treatment for DS will most likely need a polytherapy with different approaches and drugs. To fulfil this challenging task, we will develop two complementary strategies:
1) Increase expression levels of the healthy (wild type) SCN1A allele by developing CRISPR-ON virally delivered techniques and screen for small molecule drugs, strategies for which we have already obtained a proof-of-concept;
2) Identify new signaling pathways to be targeted with small molecules or antisense oligonucleotides (ASOs), which can be implicated in pathological modifications of neuronal network functions.
With this two-tiered strategy, we will maximize chances to identify genetic strategies and compounds that rescue in vitro and in vivo DS phenotypes.
As these compounds can subsequently be transferred to (pre-) clinical trials, SCN1A-UP forms a critical step in the development of treatment for DS and is therefore of utmost importance for DS patients and their families.